AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial

AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial

Source: 
BioSpace
snippet: 

AstraZeneca released new results from its ADAURA Phase III trial on Sept. 19, showing that its product Tagrisso (osimertinib) demonstrated clinically meaningful improvement in central nervous system disease-free survival (DFS) in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), after complete tumor resection. The data was presented at the Presidential Symposium of the European Society for Medical Oncology Virtual Congress 2020, and primary results were published in The New England Journal of Medicine.